Rule 1: Compounds with a sulfonamide group (-SO2NH-) have an increased potential to cause adverse effects on the liver and bile ducts, especially if they are indicated by a "1" in the SMILES strings of the dataset.
Rule 2: Molecules containing chlorine atoms may also increase the risk of causing adverse liver and bile duct effects. This applies to SMILES strings labeled as "1" or "0", but should be used cautiously due to other influencing factors like dosage and exposure duration.
Rule 3: Molecules lacking certain functional groups or structural features may decrease the risk of adverse hepatobiliary effects. These are usually represented by a "0" in the SMILES strings.
Rule 4: The presence of sulfonamide and nitro groups in a compound may increase its potential for causing adverse effects on organs like the liver. 
Rule 5: Toxicity risk increases for compounds containing aromatic rings and conjugated double bonds due to their ability to interact with biological molecules.
Rule 6: Metal ions presence in a compound may affect its potential for causing adverse effects and needs further research for a conclusive relationship.
Rule 7: The presence of a carboxylic acid group or a nitro group in a molecule can indicate potential toxicity, necessitating further safety evaluation.
Rule 8: The size and shape of the molecule can influence its ability to permeate cell membranes and thus determine its potency and bioavailability.
Rule 9: Charge of a molecule may affect its ability to cross cell membranes and reach its target site, with neutral molecules often having a higher absorption rate.
Rule 10: Phosphate group presence may increase the likelihood of hepatobiliary disorders.
Rule 11: Compounds with fluorine-containing groups may decrease the likelihood of causing adverse effects, though need considerations of conformation and electronic distribution.
Rule 12: The absence of sulfonyl or carbonyl groups may reduce the likelihood of negative effects as they are often associated with toxicity and reactivity. 
Rule 13: Gadolinium ions in a molecule may indicate toxicity levels towards liver or bile ducts. 
Rule 14: Compounds with a nitro group (-NO2) and a certain structure (eg:C[C@@]1(...)) may increase the risk of hepatobiliary disorders.
Rule 15: Presence of a sulfonyl group (-SO2R) with a specific SMILES string beginning could indicate adverse hepatobiliary effects. 
Rule 16: If a molecule's chlorine atom forms a double bond with another carbon atom or a triple bond with a nitrogen atom, it has a high probability of affecting the liver.
Rule 17: The sulfonamide group and benzene ring presence in a compound increases the possibility of hepatobiliary disorders. 
Rule 18: The presence of a furan ring and a carbonyl group also plays an important role in causing hepatobiliary disorders.
Rule 19: A fluorine atom and a chlorine atom connected to a benzene ring, or contains a carbonyl group attached to a cyclopropane ring, or contains a nitro group all increase the chances of hepatobiliary disorders. 
Rule 20: Sulfonyl and carboxylic acid groups in the molecular structure may cause liver damage. 
Rule 21: The presence of a guanidine or urea group may indicate potential liver function effects.
Rule 22: If there is a halogen atom in the molecular structure, there is a potential for adverse effects as it can react with biological molecules.
Rule 23: Halogen atoms like chlorine and fluorine, or sulfonamide groups, influence the chemical and physical properties of a compound and can lead to liver damage or hepatobiliary disorders.
Rule 24: A nitro group and a conjugated double bond system increases the likelihood of hepatobiliary disorders.
Rule 25: Specific substructures (e.g., benzene ring-nitro group or guanidine group-chlorinated carbohydrate) in a compound may signal potential liver function side effects.
Rule 1: Molecules containing a halogen atom can potentially have adverse effects on the liver and bile ducts. 
Rule 2: A molecule that contains a carboxylic acid group attached to an aromatic ring may present a higher risk of harm to the liver and bile ducts if it also contains features that increase its lipophilicity.
Rule 3: Molecules containing functional groups or atoms such as sulfur or nitrogen are more likely to cause liver and bile duct damage. 
Rule 4: The presence of a chlorine atom and a benzene ring in a molecule may lead to hepatobiliary disorders.
Rule 5: If a molecule contains a nitrogen atom bonded to two carbon atoms and has a double bond between those two carbons, it may have potential hepatobiliary disorders.
Rule 6: The potential for hepatobiliary disorders also increases with a molecule featuring a sulfur atom bonded to a carbon atom and an oxygen atom, with a triple bond present between those two atoms.
Rule 7: Molecules containing a sulfonyl group and a carbonyl group in their structures risk causing hepatobiliary disorders.
Rule 8: A molecule that contains a chlorine atom attached to a carbon atom adjacent to a nitrogen has an increased risk of adverse hepatobiliary effects.
Rule 9: Molecules containing a nitro group and a benzene ring in their structures can potentially cause disorders related to hepatobiliary.
Rule 10: Molecules that include a phosphate group and a carbonyl group risk causing hepatobiliary disorders.
Rule 11: Molecules containing a sulfonamide group and a fluorine atom are also a potential risk for adverse effects related to hepatobiliary disorders.
Rule 12: If a molecule contains a carbonyl group and a chlorine atom, it may not cause adverse effects related to hepatobiliary disorders.
Rule 13: Molecules with the presence of a benzene ring and a cyano group may not cause hepatobiliary disorders.
Rule 14: Molecules with functional groups such as a carboxylic acid or its derivatives are likely to cause hepatotoxicity and other liver-related issues and hence increases the likelihood of causing adverse effects in the body.
Rule 15: Molecules that contain aromatic rings are prone to increase risk because of their ability to interact with biological systems.
Rule 16: Large and complex structures in molecules are more likely to interact with biological targets and hence are prone to cause adverse effects.
Rule 17: A molecule with a positive charge on its nitrogen atom or a functional group such as -CN or -NO2 is likely to cause potential hepatotoxicity.
Rule 18: The presence of conjugated double bonds and aromatic rings in a molecule can lead to adverse effects.
Rule 19: Molecules not containing specific functional groups or structural features may decrease their potential for causing adverse effects.
Rule 20: The presence of amides and sulfonamides in a compound can cause adverse effects on the liver and other organs.
Rule 21: The presence of multiple aromatic rings and halogen atoms in a compound indicate its chemical reactivity and stability, potentially leading to adverse effects.
Rule 22: Molecules with a high degree of symmetry and complexity have a higher risk due to its likelihood of interacting with biological targets.
Rule 23: If a molecule contains a sulfonamide group and a nitro group, or a conjugated system of double bonds between two aromatic rings, it may cause hepatobiliary disorders.
Rule 24: Compounds containing halogen atoms like chlorine, fluorine can exhibit various toxicological effects and hence must be carefully evaluated.
Rule 25: The presence of a sulfonamide group and a benzene ring or a chlorine atom attached to a carbon atom adjacent to a carbonyl group in a molecule may have the potential to cause hepatobiliary disorders.
Rule 26: Molecules containing a benzimidazole ring, a sulfonamide group, and a nitro group may have the potential to cause hepatobiliary disorders.
Rule 27: If the molecular structure contains a functional group such as -COOH or -OH, it may lead to hepatotoxicity and other liver-related issues.
Rule 28: If a molecule contains a benzene ring, it may also have the potential to cause hepatobiliary disorders.
Rule 1: Molecules with a functional group such as sulfonamide or nitro group can result in adverse liver and kidney effects as they increase toxicity. Avoid such molecules.
Rule 2: Molecules with high degree of conjugation between pi bonds increase risk of toxicity due to their ability to bind to proteins and enzymes, and thus should be evaluated for potential adverse effects.
Rule 3: Compounds containing metal ions like iron or calcium might have toxic effects on the body depending on their concentration and exposure time, as they can interfere with various metabolic processes and cause cellular damage. Hence, such substances should be monitored and excessive intake avoided.

Rule 4: The first data set rule identifies that if a molecule contains a cyano group (-CN), and a sulfonamide group (-SO2NH2), it can cause adverse hepatobiliary disorders. This applies to molecules represented by SMILES strings C(CNCCNCCN)N and CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3.
Rule 5: The second data set rule is, molecules containing a quinolone ring system can cause adverse hepatobiliary disorders. This applies to molecules defined by SMILES strings CC1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O and CCC[C@@H](C(=O)OCC)N[C@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.
Rule 6: As per the third data set rule, molecules with a carboxylic acid group (-COOH) and a conjugated double bond system might pose a potential risk to hepatobiliary disorders.

Rule 7: Molecules containing a cyano group (-CN) and a conjugated system between two double bonds or triple bonds separated by one carbon atom, have potential to cause hepatobiliary disorders. Applicable to molecules like SMILES strings C1=CC(=CN=C1)C(=O)[O-] 1 and CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C 1.
Rule 8: A molecule with a sulfonamide group (-SO2NH-) and a carbonyl group (-C=O) connected via a nitrogen atom are less likely to cause hepatobiliary disorders. Relevant to molecules like, SMILES string CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=CCS3)C(=O)O 0.
Rule 9: Molecules containing a cyclopropane ring and a hydroxyl group (-OH) attached to a carbon atom adjacent to the ring may cause hepatobiliary disorders. It applies to molecule examples like SMILES string CCC(C)OOCC(C)(C)Oc1ccc(cc1)c2ccccc2 1.
